1. Collaborative Group on Hormonal Factors in Breast Cancer. Breast Cancer and HRT: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 1047-1059
   
   
2. Dale E, Vessey M P, Hawkins M M, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348:977-80
   
   
3. Sturdee D W, Ulrich L G, Barlow D H, Wells M, et al. The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy. Br J Obstet Gynecol 2000; 107: 1392-1400
   
   
4. Mosca L, Collins P, Herrington D M, et al. Hormone replacement therapy and cardiovascular disease : a statement for healthcare professionals from the American Heart Association. Circulation 2001; 104:499-503.
   
   
5. Nachtigall LB, Lagrega L, Nachtigall LE. The effect of isoflavones derived from red clover on vasomotor symptoms and endometrial thickness. Proceedings 81st Annual Meeting US Endocrine Society 1999; June 1999, San Diego.
   
   
6. Tice JA, Ettinger B, Ensrud K et al. Phytoestrogen supplements for the treatment of hot flashes: The isoflavone clover extract (ICE) study. A randomized controlled trial. JAMA 2003; 290:207-214.
   
   
7. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results for the Women's Health Initiative Randomized controlled trial JAMA 2002;288:321-333
   
   
8. Hulley S,Grady D,Bush T, et al. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-613.
   
   
9. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-427
   www.thelancet.com
   
   
10. Managing the menopause. British Menopause Society Council consensus statement on hormone replacement therapy. Journal of the British Menopause Society 2003; Vol.9, No.3: 129-131
    
    
11. Loprinzi CL, Kugler JW, Sloan JA et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000; 356:2059-2063.
    
    
12. Guttuso T Jr, Kurlan R, McDermott MP et al. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003; 101:337-345.
    
    
13. Bisphosphonates for osteoporosis. Drug Ther Bull 2001; 39:68-72.
    
    
14. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999; 282:637-645.
    
    
15. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. JAMA 1999; 261:2189-2197.
    
    
16. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344:1434-1441.
    
    
17. Rodriguez-Martinez MA, Garcia-Cohen EC. Role of Calcium++ and vitamin D in the prevention and treatment of osteoporosis. Pharmacol Ther 2002; 93:37-49.
    
    
18. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N.Engl J Med 1994; 331:347-352.
    
    
19. Leonetti H, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol 1999; 94:225-228.
    
    
20. Wren BG, Champion SM, Willetts K et al. Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods and quality of life for postmenopausal women. Menopause 2003; 10:13-18.
    
    
21. Cushman M, Kuller L, Prentice R. et al, for the Women's Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573-1580.
    
    
22. Lowe GD, Upton MN, Rumley A et al. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein - a cross-sectional population survey. Thromb Haemost 2001;86:550-556.
    
    
23. Ojoo J, Kastelik J, Morice A. The respiratory system and the menopause. Journal of the British Menopause Society 2001; Vol.7, No.4:168-173.
    
    
24. Bollapragada S, Panigrahy R, Mander T. Hormone replacement therapy and fibroids. Journal of the British Menopause Society 2002; Vol.8, No.4:157-158.
    
    
25. Fraser W. Pathogenesis, prevention and treatment of transplant-associated osteoporosis. Journal of the British Menopause Society 2001; Vol.7, No.1:9-14.
    
    
26. Eaton S, Webster J, Allahabadia A. Thyroid disease and the menopausal woman. Journal of the British Menopause Society 2003; Vol.9, No.2:82-84.
    
    
27. Parker S. Follicle stimulating hormone: facts and fallacies. Journal of the British Menopause Society 2004; Vol.10, No.4:166-168.
    
    
28. N.Biglia, R.Torta, R.Roagna, F Maggiorotto, F. Cacciari, R.Ponzone, F. Kubatzki, P.Sismondi.
    Evaluation of low-dose venlafaxine hydrochloride for the therapy of hot flushes in breast cancer survivors. Maturitas. Volume 52, issue1, pages 78-85.Sept 2005.
    
    
29. C.Kaari, M.A.Haidar, J.M.S.Junior et al.
    Randomized clinical trial comparing conjugated equine estrogens and isoflavones in postmenopausal women: a pilot study. Maturitas. Volume 53, issue 1, pages 49-58. January 2006.
    
    
30. Myocardial infarction risk and hormone replacement: Differences between products. C.S.de Vries, S.E.Bromley, R.D.T.Farmer. Maturitas. Volume 53, Issue 3, pages 343-350.
    
    
31. Risk of stroke and hormone replacement therapy. Cairu Li, Gunnar Engstrom, Bo Hedblad et al. Maturitas Vol 54, Issue 1, April 2006, pages 11-18.
    
    
32. A critique of Women's Health Initiative Studies (2002-2006). Clark J Nuclear Receptor Signaling (2006) 4, e023.
    
    
33. Prevalence of premature ovarian failure in monozygotic and dizygotic twins. Human Reproduction. doi:10.1093/humanrep/del382.
    
    
34. Bardia A, Hartmann LC, Vachon CM, Vierkant RA, Wang AH, Olson JE, Sellers TA, Cerhan JR. Recreational physical activity and risk of postmenopausal breast cancer based on hormone receptor status. Arch Intern Med. 2006 Dec 11; 166(22):2478-83.
    
    
35. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol 2006 Dec; 108(6):1354-60.
    
    
36. Effects of low-dose continuous combined hormone replacement therapy on glucose homeostasis and markers of cardiovascular risk in women with type 2 diabetes. Kernohan AF, Sattar N, Hilditch T, Cleland SJ, Small M, Lumsden MA, Connell JM, Petrie JR. Clin Endocrinol (Oxf). 2007 Jan;66(1):27-34.
    
    
37. Tibolone therapy in breast cancer survivors: A retrospective study. Goutzioulis M, Vavilis D, Agorastos T, Konstantinidis T, Pantazis K, Goutzioulis A, Goulis DG, Makedos G, Bontis JN. J obstet Gynaecol Res. 2007 Feb;33(1):68-73.
    
    
38. Isoflavone treatment for acute menopausal symptoms. Cheng G, Wilczek B, Warner M, Gustafsson JA, Landgren BM. Menopause. 2007 Feb 6 (epublication)
    
    
39. Canonico M, Oger E, Plu-Bureau G et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007 Feb 20;115(7):840-5.
    
    



40. Breast cancer incidence and hormone replacement therapy: Results from the MISSION study, prospective phase. Espie M, Daures JP, Chevallier T, Mares P, Micheletti MC, de Reilhac P. Gynecol Endocrinol. 2007 Jul;23(7):391-7.)
    
    



41. Body composition during treatment with conjugated estrogens with and without medroxyprogesterone acetate: analysis of the women’s Health, Osteoporosis, Progestin, Estrogen (HOPE) trial. Ian H Thorneycroft, Robert Lindsay, James Pickar. American Journal of Obstetrics and Gynecology. August 2007. Volume 197;Issue 2:137
    
    



42. Interactions between intakes of alcohol and postmenopausal hormones on risk of breast cancer. Nielson NR, Gronbaek M. Int J Cancer 2007 Oct 26; [Epub ahead of print]



43. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Gambacciani M, Cappagli B, Ciaponi M, Pepe A, Vacca F, Genazzani AR Maturitas. 2007 Dec 1 [Epub ahead of print]



44. Estrogen May Be Neuroprotective After All. Caroline Helwick, Laurie Barclay, Brande Niole Martin. Society of Nuclear Medicine 2008 Annual Meeting: Abstract 973. Presented June 16, 2008.